Endocrine Abstracts

Introduction: Following a National training programme for Endocrinologists to provide RAI treatment for benign thyroid disease, the ESHT NHS Trust started Radioactive iodine (RAI) treatment for benign thyroid disease a couple of years ago. Previously ESHT trust patients were referred to neighbouring trusts for RAI treatment.

Data/Results: The data was collected over a 12-18 month period. A total of 34 patients received RAI treatment during this period; 28 Females (82%): 6 Males (18%). 62% (21 patients) of patients had relapsing autoimmune thyrotoxicosis, 32% (11 patients) of patients had Toxic multinodular goitre and 2 patients (6%) had single toxic adenoma. 32 patients have 6 months follow up data and 17 patients have completed twelve months follow up after the RAI. 2 out of the 34 patients have not yet completed 6 months follow up. Out of 32 patients who have completed 6 months follow up after RAI, 88% have been treated (65% patient hypothyroid, 23% euthyroid) and 2 patients (6%) remained hyperthyroid (One patient is on carbimazole and thyroid tests are normal, second patient has suppressed TSH with normal FT4 without any treatment, both are under regular follow up). Out of the 17 patients who have completed 12 months follow up after the RAI treatment all (100%) have been treated (80% of patients now hypothyroid, 20% euthyroid).

Conclusion: All the Patients who has completed 12 months follow up, after single dose of RAI treatment, has responded well to the treatment. None of our patients had any side effects or complications. Some of the patients did not have the appropriate follow up appointments as recommended. Our management pathway will be reviewed to avoid this in the future.